We observed that TIPE2 loss notably reduced the CD71 expression in IKE-treated tumor PMN-MDSCs compared to IKE-treated WT tumor PMN-MDSCs, but TIPE2 deficiency did not change the CD71 expression of IKE-treated tumor M-MDSCs compared to IKE-treated WT tumor M-MDSCs (Figure 1g and Figure S1c). The gene discussed is TFRC; the disease is neoplasm.